Rationale and design of the direct oral anticoagulants for prevention of left ventricular thrombus after anterior acute myocardial infarction (APERITIF) trial
Study context
- Population
- Patients with anterior ST-elevation-myocardial infarction (STEMI) or very high-risk non- ST-elevation-myocardial infarction (NSTEMI) with involvement of the left anterior descending artery, admitted to cardiac Intensive Care Unit (ICU) within 48 hours of symptom onsetplanned sample size 560
- Planned comparison
- Dual Antiplatelet Therapy (DAPT) plus rivaroxaban 2.5mg twice daily vs DAPT alone
- Primary endpoint
- Presence of LV thrombus detected by contrast enhanced CMR
- Follow-up
- 1 month
Methodological detailsAPERITIF, investigator-initiated, multicentre, open-label, blinded end-point (PROBE), nested in the FRENCHIE registry, Secondary endpoints: Left ventricular (LV) thrombus dimension (greatest diameter), major bleedings and major CV events at 1 month, Sample size of 560 patients for 80% power to show superiority
- APERITIF
- Investigator-initiated
- Multicentre
- Open-label
- Blinded end-point (PROBE)
- Nested in the FRENCHIE registry
- Secondary endpoints: LV thrombus dimension (greatest diameter), major bleedings and major CV events at 1 month
- Sample size of 560 patients for 80% power to show superiority
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Rationale and design of the direct oral anticoagulants for prevention of left ventricular thrombus after anterior acute myocardial infarction (APERITIF) trial. Am Heart J. Published 14 September 2023. doi:10.
Summarised from the published abstract; every number is checked against it